Abstract Library

#4559 Exploring the interplay between RNA methylation and splicing dysregulation in neuroendocrine tumours

Introduction: Post-transcriptional modifications play crucial roles in regulating gene expression and cellular function. While recent findings indicate that alternative splicing dysregulation plays a key role in tumorigenic properties of neuroendocrine tumours (NETs), the role of other RNA processing mechanisms, such as N6-methyladenosine (m6A) — being the most common RNA methylation — remains largely unexplored in NETs.

Conference:

Presenting Author:

Authors: Ruiz-Palacios D, Gutiérrez Camacho L, García Vioque V, Moreno Montilla M, Blázquez-Encinas R,

Keywords: RNA methylation, splicing, neuroendocrine tumour, lung NET, pan NET,

#4546 Epigenetic exploration of mesenteric fibrosis indicates epigenetic disruption of DAXX is driving metastatic potential in small intestinal neuroendocrine tumours

Introduction: Up to 50% of patients diagnosed with small intestinal neuroendocrine tumours (SI-NETs) are affected by mesenteric fibrosis (MF) which has significant pathological effects and impacts patient mortality.

Conference:

Presenting Author: Webster A

Authors: Webster A, Martins M, Hodgetts H, Feelders R, Hofland L,

Keywords: DNA methylation, SI-NET, Mesenteric fibrosis, Epigenetics, Gene regulation, DAXX,

#4516 A methylation-based classifier for neuroendocrine tumour detection using smMIP technology

Introduction: DNA methylation plays an important role in NET pathogenesis. Distinct methylation profiles can differentiate between tumour subtypes, predict malignancy potential, and provide insights into tumour progression.

Conference:

Presenting Author:

Authors: Ibrahim J, Mariën L, Vanpoucke T, Neefs I, Vandenhoeck J,

Keywords: neuroendocrine tumour, DNA methylation, biomarker selection, IMPRESS technology, classifier model,

#4505 NET-IMPRESS: A novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies

Introduction: Previously, we showed that analysing copy number alterations (CNAs) in cell-free DNA (cfDNA) of NET patients using shallow whole genome sequencing (sWGS) is a potential biomarker for diagnosis and follow-up (PMID: 34759042). We now present NET-IMPRESS, an easy, cost-effective methylation-based assay for detecting circulating tumour DNA (ctDNA) in NET samples.

Conference:

Presenting Author:

Authors: Mariën L, Ibrahim J, de Meulenaere N, Chhajlani S, Neefs I,

Keywords: neuroendocrine tumour, liquid biopsy, DNA methylation, copy number alterations, biomarker selection, IMPRESS technology,

#4256 Epigenetic prediction of aging and metabolic traits provides insight into tumor biology in multi-focal ileal neuroendocrine tumors

Introduction: Approximately half of small intestinal neuroendocrine tumors (siNETs) are multifocal, and recent investigations into the genetic architecture of these tumors have found that they are not clonal. Due to the low mutational rate and slow growing nature of these small tumors, the ‘timing’ of the development of individual tumors has not been possible.

Conference:

Presenting Author:

Authors: Webster A, Makinen N, Ecker S, Beck S, Nakakura E,

Keywords: DNA methylation, Epigenetics, Multifocal Ileal Neuroendocrine Tumor, Multifocal Small Instestinal NET, Metabolic Traits,